Michael Von Korff1, Rod L Walker2, Kathleen Saunders2, Susan M Shortreed3, Manu Thakral2, Michael Parchman2, Ryan N Hansen4, Evette Ludman2, Karen J Sherman5, Sascha Dublin5. 1. Kaiser Permanente Health Research Institute, Seattle, WA, USA. Electronic address: vonkorff.m@ghc.org. 2. Kaiser Permanente Health Research Institute, Seattle, WA, USA. 3. Kaiser Permanente Health Research Institute, Seattle, WA, USA; Department of Biostatistics, University of Washington, USA. 4. School of Pharmacy, University of Washington, Seattle, WA, USA. 5. Kaiser Permanente Health Research Institute, Seattle, WA, USA; Department of Epidemiology, University of Washington, USA.
Abstract
BACKGROUND: No studies have assessed the comparative effectiveness of guideline-recommended interventions to reduce risk of prescription opioid use disorder among chronic opioid therapy (COT) patients. We compared the prevalence of prescription opioid use disorder among COT patients from intervention clinics that had implemented opioid dose and risk reduction initiatives for more than 4 years relative to control clinics that had not. METHODS: After a healthcare system in Washington State implemented interventions to reduce opioid dose and risks, we surveyed 1588 adult primary care COT patients to compare the prevalence of prescription opioid use disorder among COT patients from the intervention and control clinics. Intervention clinics managed COT patients at lower COT doses and with more consistent use of risk reduction practices. Control clinics cared for similar COT patients but prescribed higher opioid doses and used COT risk reduction practices inconsistently. Prescription opioid use disorder was assessed with the Psychiatric Research Interview for Substance and Mental Disorders. RESULTS: The prevalence of prescription opioid use disorder was 21.5% (95% CI=18.9% to 24.4%) among COT patients in the intervention clinics and 23.9% (95% CI=20.5% to 27.6%) among COT patients in the control clinics. The adjusted relative risk of prescription opioid use disorder was 1.08 (95% CI=0.89, 1.32) among the control clinic patients relative to the intervention clinic patients. CONCLUSIONS: Long-term implementation of opioid dose and risk reduction initiatives was not associated with lower rates of prescription opioid use disorder among prevalent COT patients. Extreme caution should be exercised by clinicians considering COT for patients with chronic non-cancer pain until benefits of this treatment and attendant risks are clarified.
BACKGROUND: No studies have assessed the comparative effectiveness of guideline-recommended interventions to reduce risk of prescription opioid use disorder among chronic opioid therapy (COT) patients. We compared the prevalence of prescription opioid use disorder among COT patients from intervention clinics that had implemented opioid dose and risk reduction initiatives for more than 4 years relative to control clinics that had not. METHODS: After a healthcare system in Washington State implemented interventions to reduce opioid dose and risks, we surveyed 1588 adult primary care COT patients to compare the prevalence of prescription opioid use disorder among COT patients from the intervention and control clinics. Intervention clinics managed COT patients at lower COT doses and with more consistent use of risk reduction practices. Control clinics cared for similar COT patients but prescribed higher opioid doses and used COT risk reduction practices inconsistently. Prescription opioid use disorder was assessed with the Psychiatric Research Interview for Substance and Mental Disorders. RESULTS: The prevalence of prescription opioid use disorder was 21.5% (95% CI=18.9% to 24.4%) among COT patients in the intervention clinics and 23.9% (95% CI=20.5% to 27.6%) among COT patients in the control clinics. The adjusted relative risk of prescription opioid use disorder was 1.08 (95% CI=0.89, 1.32) among the control clinic patients relative to the intervention clinic patients. CONCLUSIONS: Long-term implementation of opioid dose and risk reduction initiatives was not associated with lower rates of prescription opioid use disorder among prevalent COT patients. Extreme caution should be exercised by clinicians considering COT for patients with chronic non-cancer pain until benefits of this treatment and attendant risks are clarified.
Authors: Christina Korownyk; Danielle Perry; Joey Ton; Michael R Kolber; Scott Garrison; Betsy Thomas; G Michael Allan; Cheryl Bateman; Raquel de Queiroz; Dorcas Kennedy; Wiplove Lamba; Jazmin Marlinga; Tally Mogus; Tony Nickonchuk; Eli Orrantia; Kim Reich; Nick Wong; Nicolas Dugré; Adrienne J Lindblad Journal: Can Fam Physician Date: 2019-05 Impact factor: 3.275
Authors: Christina Korownyk; Danielle Perry; Joey Ton; Michael R Kolber; Scott Garrison; Betsy Thomas; G Michael Allan; Cheryl Bateman; Raquel de Queiroz; Dorcas Kennedy; Wiplove Lamba; Jazmin Marlinga; Tally Mogus; Tony Nickonchuk; Eli Orrantia; Kim Reich; Nick Wong; Nicolas Dugré; Adrienne J Lindblad Journal: Can Fam Physician Date: 2019-05 Impact factor: 3.275
Authors: Johannes M Just; Norbert Scherbaum; Michael Specka; Marie-Therese Puth; Klaus Weckbecker Journal: PLoS One Date: 2020-07-23 Impact factor: 3.240
Authors: Johannes Maximilian Just; Fabian Schwerbrock; Markus Bleckwenn; Rieke Schnakenberg; Klaus Weckbecker Journal: BMJ Open Date: 2019-04-03 Impact factor: 2.692
Authors: Morgane Guillou-Landreat; Bertrand Quinio; Jean Yves Le Reste; Delphine Le Goff; Jérôme Fonsecca; Marie Grall-Bronnec; Antoine Dany Journal: Int J Environ Res Public Health Date: 2021-02-21 Impact factor: 3.390
Authors: Kinna Thakarar; Amoli Kulkarni; Sara Lodi; Alexander Y Walley; Marlene C Lira; Leah S Forman; Jonathan A Colasanti; Carlos Del Rio; Jeffrey H Samet Journal: J Int Assoc Provid AIDS Care Date: 2021 Jan-Dec